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Rationale: Lung transplantation offers the only survival option for
patients with cystic fibrosis (CF) with end-stage pulmonary disease.
Infectionwith Burkholderia species is typically considered a contrain-
dication to transplantation in CF. However, the risks posed by
different Burkholderia species on transplantation outcomes are
poorly defined.
Objectives: To quantify the risks of infectionwith Burkholderia species
on survival before and after lung transplantation in patientswithCF.
Methods: Multivariate Cox survival models assessed hazard ratios of
infection with Burkholderia species in 1,026 lung transplant candi-
dates and 528 lung transplant recipients. Lung allocation scores,
incorporating Burkholderia infection status, were calculated for
transplant candidates.
Measurements and Main Results: Transplant candidates infected with
different Burkholderia species did not have statistically different
mortality rates. Among transplant recipients infected with B. cen-
ocepacia, only those infected with nonepidemic strains had signifi-
cantly greater post-transplant mortality compared with uninfected
patients (hazard ratio [HR], 2.52; 95% confidence interval [CI],
1.04–6.12; P 5 0.04). Hazards were similar between uninfected
transplant recipients and those infected with B. multivorans (HR,
0.66; 95% CI, 0.27–1.56; P 5 0.34). Transplant recipients infected
with B. gladioli had significantly greater post-transplant mortality
than uninfected patients (HR, 2.23; 95% CI, 1.05–4.74; P 5 0.04).
Oncehazards for species/strainwere included, lungallocationscores
of B.multivorans–infected transplant candidateswere comparable to
uninfected candidate scores, whereas those of candidates infected
with nonepidemic B. cenocepacia or B. gladioliwere lower.
Conclusions: Post-transplant mortality among patients with CF
infectedwith Burkholderia varies by infecting species. This variability
should be taken into account in evaluating lung transplantation
candidates.
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Therapeutic options for persons with cystic fibrosis (CF) with
end-stage pulmonary disease are limited. Although some
patients and their caregivers choose to pursue only aggressive
medical therapy, other patients, if deemed eligible, may be
offered the opportunity to undergo lung transplantation. Al-
though CF is the third most common diagnosis among lung
transplant recipients overall (behind idiopathic pulmonary fibrosis
and chronic obstructive pulmonary disease), it is the most com-
mon indication for lung transplantation in pediatric patients (1).
Approximately 180 patients with CF underwent lung transplan-
tation per year in the United States between 1996 and 2005 (1).
Estimates of clinical benefit after lung transplantation in
patients with CF vary. Hosenpud and colleagues (2) used a
retrospective time-dependent nonproportional hazard analysis
to assess the risk of mortality after transplantation relative to
that for patients on the transplant waiting list, and showed
a significant benefit from transplantation in CF. Aurora and
colleagues (3) used a proportional hazards model in a retrospec-
tive analysis to calculate a univariate hazard ratio (HR) showing
that transplantation was significantly associated with survival
after correction for several variables of prognostic significance
in CF. In contrast, Liou and coworkers (4, 5) used a multivari-
able logistic regression survivorship model for CF to show that
the majority of patients with CF have equivocal or negative
survival effects from lung transplantation. More recently, Liou
and coworkers used a proportional hazards model to again
estimate that the majority of children with CF wait-listed for
lung transplantation would actually have a significant risk of
harm associated with the procedure (6). Thus, the role of lung
transplantation in CF is controversial, but it is increasingly clear
that selection of the most appropriate candidates for trans-
plantation (i.e., those with the greatest likelihood of benefit) is
critical.
To better allocate lungs for transplantation, the Scientific
Registry of Transplant Recipients (SRTR) and the Organ
Procurement and Transplantation Network (OPTN) developed
a lung allocation score that estimates each patient’s urgency and
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Burkholderia infection is considered a contraindication to
lung transplantation in cystic fibrosis. However, the risks
posed by different Burkholderia species on outcomes after
lung transplantation in cystic fibrosis are not well defined.
What This Study Adds to the Field
This multivariate analysis shows that the risk of poor
outcome after lung transplantation varies between Bur-
kholderia species. These relative risks should be taken into
account in evaluating lung transplantation candidates.
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potential transplant benefit based on probability models of lung
wait-list and post-transplant survival (7). In May 2005, the
OPTN implemented a national policy for lung allocation,
prioritizing patients according to their lung allocation score.
Data used in designing the lung allocation score, which incor-
porates variables shown in previous analyses to be important
predictors of outcomes in lung transplantation in CF, were
limited to those collected by the OPTN in its original de-
velopment. The lung allocation scoring system is intended to be
updated at frequent intervals, particularly as additional predic-
tors are identified and merged with OPTN data on patient
outcomes. For example, in March of 2007, PaCO2 and measures
of PaCO2 change over a 6-month period were approved by the
OPTN Board of Directors for inclusion in the lung allocation
score based on such an analysis (8, 9). Additional predictors of
mortality on the lung waiting list or after transplantation that
can be validated within the OPTN patient population are of
interest to national lung allocation policy makers.
Much of the morbidity and mortality associated with lung
transplantation in CF are attributed to postoperative infectious
complications. Infections with bacteria that exhibit broad-range
antibiotic resistance have been found, not surprisingly, to be
most problematic (10–14). Several studies during the 1990s
identified infection with Burkholderia cepacia, in particular, to
be associated with post-transplantation infectious complications
and poor outcomes (14–20). Consequently, lung transplantation
in persons infected with Burkholderia species is controversial
(21, 22), and many transplant centers currently exclude such
patients from transplantation waiting lists. However, early
studies identifying B. cepacia as a risk in transplant recipients
were performed before the realization that several distinct
species constitute what is now referred to as the B. cepacia
complex. These species, although very closely related phyloge-
netically and phenotypically, vary considerably in the frequency
with which they cause infection in patients with CF. Together,
B. cenocepacia and B. multivorans account for approximately
85% of B. cepacia complex infection in the United States (23).
Emerging data further suggest that species within the B. cepacia
complex also differ with respect to their virulence in this patient
population (24). The risk associated with infection with B. gladioli,
which, although not a member of the B. cepacia complex, also
causes chronic respiratory tract infection in patients with CF,
has not been assessed.
We undertook a retrospective multivariate survival analysis
to assess the hazards of infection with different Burkholderia
species in patients with CF being considered for or having
received lung transplants. On the basis of the results of these
analyses, we calculated a lung allocation score for wait-listed
patients that includes infection status parameter estimates in the
assessment of patient urgency and patient benefit.
METHODS
Patient Population and Control Subjects
This study was approved by the University of Michigan’s Institutional
Review Board for Human Subject Research, the Cystic Fibrosis
Foundation (CFF) Patient Registry Committee, and the Health
Resources and Services Administration’s (U.S. Department of Health
and Human Services) SRTR project officer.
Lung waiting list cohort. We identified all individuals from whom a
sputum culture isolate was confirmed asBurkholderia by theBurkholderia
cepacia Research Laboratory and Repository (BcRLR), and who re-
ceived care in CFF-accredited care centers in the United States and
were registered in the CFF Patient Registry (Bethesda, MD). Among
this cohort of 1,541 Burkholderia-infected patients, 171 were registered
as lung transplant candidates with the SRTR between January 1, 1997,
and December 31, 2006, and were at least 12 years old at the time they
entered the lung transplant waiting list (‘‘waiting list cases’’). These 171
patients received care, over the course of this 10-year interval, in 209
CF care centers in the United States. There were an additional 2,105
patients with CF on the lung transplant waiting list who were at least 12
years old and not known to be infected with Burkholderia based on
data from the CFF Patient Registry and the BcRLR (‘‘waiting list
control subjects’’). To eliminate era effects due to differential distri-
bution of listing dates between cases and control subjects, we selected
five waiting list control subjects for each of the 171 Burkholderia-
infected waiting list cases matched on year of listing for transplanta-
tion. Mortality data were supplemented as needed by using the Social
Security Death Master File. The resulting 171 waiting list cases and 855
waiting list control subjects created a dataset of 1,026 ‘‘wait-listed
candidates’’ for analysis.
Transplant recipient cohort. We identified 88 Burkholderia-infected
patients with CF who were registered in the SRTR database as having
received a lung transplant between January 1, 1997, and December 31,
2006, and who were at least 12 years old at the time of their transplant
(‘‘transplanted cases’’). These 88 patients received lung transplanta-
tions in 23 transplant centers in the United States. There were an
additional 1,426 patients with CF at least 12 years old who received
a lung transplant during the same period but who were not known to be
infected with Burkholderia before transplantation (‘‘transplanted con-
trol subjects’’). Five transplanted control subjects were matched to
each transplanted case by year of transplant, creating a dataset of
528 ‘‘transplant recipients’’ (88 transplanted cases and 440 transplanted
control subjects). Again, mortality data were supplemented by using
the Social Security Death Master File.
A summary view of the groups analyzed in this study is shown in
Figure 1.
Microbiologic Analysis
Bacterial isolates recovered from CF respiratory specimens were
confirmed as Burkholderia species by using 16S rDNA and recA
species-specific polymerase chain reaction, and recA restriction frag-
ment length polymorphism analyses as previously described (25, 26).
Bacterial genotyping, using repetitive extragenic palindromic element
polymerase chain reaction typing as previously described (27), was
performed on isolates from all Burkholderia-infected patients to
Figure 1. Summary view of population studied. The numbers in
parentheses for each group indicate the numbers of lung transplant
candidates/recipients identified in the Scientific Registry of Transplant
Recipients between January 1, 1997, and December 31, 2006. Other
Bcc 5 B. cepacia complex species other than B. cenocepacia and
B. multivorans.
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determine strain type (and to identify previously reported epidemic B.
cenocepacia strains, such as strain PHDC and the Midwest clone).
Statistical Analysis
Multivariate Cox models were used to examine the associations
between Burkholderia infection status and waiting list and post-trans-
plant mortality in the context of the SRTR/OPTN lung allocation score
system implemented in May 2005 (7). Modified lung allocation scores
that include Burkholderia infection status together with current lung
allocation score factors were then calculated for the waiting list cases.
Two-sample t tests were used to compare demographics of continuous
variables between Burkholderia-infected and uninfected patients. Fisher
exact tests were used to compare categorical demographic information
between these groups.
Waiting list survival models. Two multivariate Cox models were
used to assess the association between Burkholderia infection and the
mortality hazard among the 1,026 wait-listed candidates (28). In the
first model, the 171 Burkholderia-infected wait-listed cases were cat-
egorized as infected with B. cenocepacia, B. multivorans, B. gladioli,
or ‘‘other Bcc’’ (the latter category included patients infected with
Burkholderia species other than B. cenocepacia, B. multivorans, or
B. gladioli). The second model differed from the first only in that the
B. cenocepacia–infected patients were further subdivided into three
groups based on bacterial strain type (i.e., strain PHDC, the Midwest
strain, and, as a single group, all other B. cenocepacia strains). Both
models used time-dependent covariates for infection status and dura-
tion of Burkholderia infection, censored follow-up at transplant, and
adjusted for lung allocation score factors affecting CF waiting list
survival. These latter factors included age at waiting list entry, diabetes,
six-minute-walk distance, 150 ft, New York Heart Association (NYHA)
functional status, FVC (% predicted), pulmonary arterial systolic
pressure, O2 required at rest (L/min), body mass index, and mechanical
ventilation at the time of wait-listing. In these analyses, we assumed
that these factors, which previously have been shown to be associated
with mortality in lung transplantation, also apply to Burkholderia-
infected patients with CF undergoing or being considered for trans-
plantation (7). To estimate adjusted 1- and 5-year survival probabilities
for both infected and uninfected wait-listed candidates, Cox survival
curves fitted to the 1,026 wait-listed candidates were estimated for
a typical patient profile differing only by infection status. Time infected
was taken to be zero for uninfected patients and 2 years for infected
groups in reported survival estimates by infection status; approximately
63% (108/171) of patients had been infected at least this long at listing.
Post-transplant survival models. Two other multivariate Cox models
were used to assess the hazards of infection in the 528 lung transplant
recipients. In the first model, the 88 transplanted cases were catego-
rized as infected with B. cenocepacia, B. multivorans, B. gladioli, or
other Bcc at the time of transplant. The second model differed from the
first only in that the B. cenocepacia–infected patients were again
further subdivided into three groups: those infected with strain PHDC,
those infected with the Midwest clone, or, as a group, those infected
with any other B. cenocepacia strains. Both models adjusted for time
infected before transplant as well as the following lung allocation score
factors affecting CF survival: age at time of transplant, NYHA
functional status, serum creatinine, and mechanical ventilation at the
time of transplantation. The 1- and 5-year adjusted post-transplant
survival probabilities by infection status were obtained using the
estimates from the multivariate Cox model fit to the data on the 528
transplant recipients, estimated for a typical recipient profile differing
only by infection status. These survival estimates assumed zero time
infected for uninfected patients and 2 years’ time infected before
transplant for infected patients. Significant results are reported at the
a 5 0.05 level.
Projected benefit. Projected transplant benefit is estimated by
subtracting the area under a patient’s waiting list survival curve from
the area under the patient’s post-transplant survival curve during a
specified time interval. The result is expressed as the expected days
gained from the transplant during the time interval. The projected
benefit during the first year and during the first 5 years after trans-
plantation, if a patient were to receive lung transplantation at the time
of listing, was calculated for each of the 1,026 wait-listed candidates. In
this calculation, Cox-based wait-list and post-transplant survival curves
were estimated specific to each patient according to existing lung
allocation score risk factors and Burkholderia infection status.
Lung allocation scores. Models estimating projected wait-listed
candidate and transplant recipient survival according to individual risk
factors also were used to calculate an updated lung allocation score (7)
for each of the 1,026 wait-listed candidates that includes Burkholderia
infection status information. The lung allocation score is based on (1)
urgency, defined by the number of days a patient would be expected to
live during the next year without a transplant, and (2) benefit, defined
by the number of additional days a patient would be expected to live
during the next year if he or she were to receive a lung transplant.
Patient urgency is typically estimated using the area under a patient-
specific Cox-based waiting list survival curve up to a year. Patient
benefit is estimated as described above. The resulting raw lung allo-
cation score is defined as the patient benefit measure minus the patient
urgency measure. The score is then normalized to produce a range
from 0 to 100 by calculating 100 3 (raw lung allocation score 1 730)/
1,095.
RESULTS
Multivariate Analysis of Wait-Listed Candidates
Few significant differences in demographic and clinical features
were found between the 1,026 infected and uninfected wait-
listed candidates (Table 1). B. multivorans–infected patients
had higher functional status classifications than uninfected
patients, with 55.4 versus 37.4%, respectively, in NYHA
functional status 2 (P5 0.01). A significantly greater proportion
of patients infected with other Bcc (i.e., those infected with
TABLE 1. WAIT-LISTED CANDIDATES’ DEMOGRAPHIC MEANS OR PROPORTIONS BY INFECTION STATUS






Other* B. multivorans Other Bcc† B. gladioli
Variable (n 5 855) (n 5 62) (n 5 13) (n 5 17) (n 5 32) (n 5 56) (n 5 23) (n 5 30)
Age, yr 27.4 28.0 28.7 25.5 29.0 27.3 27.7 27.6
FVC, % predicted 44.7 46.0 44.9 44.7 47.1 43.6 50.1 45.1
PA systolic pressure, mm Hg 37.9 40.3 31.2 44.0 43.7 35.6 36.7 40.5
Resting O2 requirement, L/min 1.6 1.6 2.2
‡ 1.4 1.4 1.8 1.1 1.1
BMI 19.1 19.2 20.6 18.2 19.1 20.1 18.7 19.1
Diabetic, % 27.9 27.5 60.0‡ 13.3 23.1 35.0 36.8 28.0
Six-minute-walk , 150 ft, % 6.7 6.4 10.0 8.3 4.0 0.0 0.0 4.0
NYHA functional status, %
2 37.4 51.6‡ 61.5 58.8 43.8 55.4‡ 47.8 33.3
3 1.4 0.0 0.0 0.0 0.0 3.6 13.0‡ 3.3
On ventilator, % 1.0 0.0 0.0 0.0 0.0 0.0 8.7‡ 0.0
Definition of abbreviations: BMI 5 body mass index; NYHA 5 New York Heart Association.
* ‘‘B. cenocepacia Other’’ includes all B. cenocepacia strains that are not strain PHDC or Midwest clone.
† ‘‘Other Bcc’’ includes all B. cepacia complex species other than B. cenocepacia and B. multivorans.
‡ Statistically significant difference from uninfected patients at P , 0.05. At this level of significance with 70 tests, 3.5 spurious differences are expected.
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species other than B. cenocepacia or B. multivorans) were
classified as NYHA functional status 3 when compared with
uninfected patients (13.0 vs. 1.4%, respectively; P 5 0.006) and
were more often ventilated (8.7 vs. 1.0%, P 5 0.03). Patients
infected with B. cenocepacia strain PHDC required more
oxygen at rest on average than uninfected patients (2.2 vs.
1.6 L/min, respectively; P 5 0.049) and were more frequently
diabetic (60.0 vs. 27.9%, P 5 0.036). These differences might
indicate a trend toward somewhat reduced capacity among
infected patients when compared with their uninfected counter-
parts, although the prognosis tended to be poor for all patients
with CF on the lung transplant waiting list.
Once adjusted for lung allocation score factors, the HRs and
estimated 1- and 5-year adjusted survival probabilities among
the 1,026 wait-listed candidates did not differ significantly by
infection status (Table 2), although considerable variability was
seen in observed event rates in these small groups over time
(Figure 2A; see Figure E1A in the online supplement for
unadjusted wait-list survival estimates by species/strain). The
hazard associated with time infected before waiting list entry
was not statistically significant (HR, 1.00; 95% confidence
interval [CI], 0.94–1.07; P 5 0.97). The indices of concordance
for model fit were approximately 70%, indicating correct
ordering of mortality by the model in 70% of pairs selected
from the cohort with verifiable ordering of outcomes.
Multivariate Analysis of Transplant Recipients
Few significant differences in demographic and clinical features
were noted among the 528 lung transplant recipients (Table 3).
Transplant recipients infected with B. cenocepacia strain PHDC
or with B. cepacia complex species other than B. cenocepacia
or B. multivorans were significantly more often classified with
NYHA functional status 3 compared with uninfected recipients
(P 5 0.03 and 0.007, respectively); most uninfected recipients
were classified as NYHA functional status 1 or 2. Otherwise,
lung allocation score factors relating to prognosis after trans-
plant were similar between infected and uninfected recipients.
Once adjusted for lung allocation score factors, the HRs and
1- and 5-year survival probabilities for lung transplant recipients
showed several significant differences by infection status (Table 4).
Lung transplant recipients infected with B. gladioli had signif-
icantly higher post-transplant mortality than uninfected patients
(HR, 2.23; 95% CI, 1.05–4.74; P 5 0.04) and recipients infected
with B. multivorans (HR, 3.41; 95% CI, 1.23–9.46; P 5 0.02)
(Figure 2B; see Figure E1B for unadjusted transplant sur-
vival estimates by species/strain). Survival was similar between
B. multivorans–infected recipients and uninfected recipients
(HR, 0.66; 95% CI, 0.27–1.56; P 5 0.34). Hazards for recipients
infected with nonepidemic B. cenocepacia strains (i.e., strains
other than PHDC or the Midwest clone) were also high when
compared with uninfected recipients (HR, 2.52; 95% CI, 1.04–
6.12; P 5 0.04) or B. multivorans–infected recipients (HR, 4.39;
95% CI, 1.62–11.85; P 5 0.0035). The hazard associated with
time infected before transplant was not statistically significant
(HR, 1.03; 95% CI, 0.94–1.13; P 5 0.58). The indices of
concordance for post-transplant model fit were approximately
60%.
Projected Transplant Benefit and Modified Lung
Allocation Scores
Projected 1- and 5-year benefits of transplantation, if trans-
planted at the time of initial wait-listing, and modified lung
allocation scores for the 1,026 wait-listed candidates were
calculated using data recorded at the time of each patient’s
listing and using existing lung allocation score factors, infection
status, and duration of infection before listing. Projected benefit
for the first year after transplantation was positive in 270 (26.3%)
patients (Figure 3A); benefit was projected to be positive for
567 (55.3%) patients over the course of the first 5 years after
transplantation (Figure 3B). Modified lung allocation scores for
the wait-listed patients that include infection status in the
assessment of patient urgency and benefit are shown in Figure 4.
There was substantial variability in the lung allocation scores,
and there were many infection categories that had scores
overlapping with uninfected patients once all risk factors were
taken into account. As expected, B. multivorans–infected can-
didates have scores similar to those of uninfected patients, as
did other infection categories that did not have statistically
different survival from that of uninfected patients. However,
B. gladioli and nonepidemic strains of B. cenocepacia tended to
have many scores below 30, which would typically put these
candidates at the bottom 5% of the waiting list for lung alloca-
tion. As a measure of robustness to proportional hazards
assumptions in the mortality models, we refit wait-list and
post-transplant models, stratifying baseline hazard calculation
by Burkholderia species/strain. Lung allocation scores were
TABLE 2. ADJUSTED HAZARD RATIOS, 1- AND 5-YEAR WAITING LIST SURVIVAL RATES* BY INFECTION
STATUS (n 5 1,026)
HR 1-Year Survival, % 5-Year Survival, %
Species/Strain n (%) (95% CI) P† (95% CI) (95% CI)
Uninfected, reference group 855 (83) 1.00 (NA) NA 80.1 (77.5–83.8) 47.3 (41.2–54.1)
B. cenocepacia‡ 62 (6) 1.46 (0.74–2.90) 0.28 82.7 (72.3–94.5) 32.3 (15.9–65.8)
B. cenocepacia PHDC 13 (1) 1.06 (0.30–3.67) 0.93 78.3 (58.1–100.0) 56.2 (34.1–92.6)
B. cenocepacia Midwest 17 (2) 1.64 (0.65–4.12) 0.29 89.0 (76.6–100.0) 36.3 (14.7–90.0)
B. cenocepacia Otherx 32 (3) 1.45 (0.68–3.11) 0.34 81.6 (67.9–98.1) 32.1 (13.7–74.9)
B. multivorans 56 (6) 1.22 (0.66–2.27) 0.52 86.5 (76.1–98.2) 28.8 (12.7–65.3)
Other Bcck 23 (2) 1.69 (0.75–3.83) 0.21 80.1 (63.4–100.0) 0.0 (NA)
B. gladioli 30 (3) 1.34 (0.66–2.74) 0.42 73.5 (57.6–93.8) 39.8 (18.7–85.0)
Definition of abbreviations: CI 5 confidence interval; HR 5 hazard ratio; NA 5 not applicable.
* Survival rates reported for average covariate profile as follows: age (yr) 5 27.41; probability of being diabetic 5 23%;
probability of having a six-minute-walk , 150 ft 5 5%; probability of being classified as functional status 2 5 39%; probability of
being classified as functional status 3 5 2%; FVC (% predicted) 5 43.25; pulmonary arterial systolic pressure (mm Hg) 5 11.93;
resting O2 requirement (L/min) 5 1.33; body mass index 5 19.02; probability of being on a ventilator 5 1%; time infected
(yr) 5 2.0.
† P value comparing hazards between infected and uninfected (reference) group.
‡ Includes results for 62 B. cenocepacia–infected patients produced through a separate parameterization of model.
x ‘‘B. cenocepacia Other’’ includes all B. cenocepacia strains that are not strain PHDC or Midwest clone.
k ‘‘Other Bcc’’ includes all B. cepacia complex species other than B. cenocepacia and B. multivorans.
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similar to the model assuming proportional hazards (correlation
between lung allocation scores 5 0.98; correlation between lung
allocation score ranks 5 0.93).
DISCUSSION
Previous studies of the impact of Burkholderia infection on
postoperative mortality in lung transplant recipients have pro-
vided conflicting results. Most studies describe poorer outcomes
among Burkholderia-infected recipients compared with non-
infected recipients, with first-year mortality rates ranging from
15 to 80% among infected patients (19, 20, 29, 30). As a result,
although current guidelines do not specifically exclude Burkhol-
deria-infected patients from transplant eligibility, many centers
have considered Burkholderia infection to be an absolute con-
traindication to transplantation.
However, most previous outcomes analyses assessing the
impact of Burkholderia in lung transplantation were performed
Figure 2. Waiting list (A) and post-transplant (B) survival
estimates obtained using hazards estimated with Cox
models, as described in the text, adjusted for current
lung allocation score factors evaluated for the average
cystic fibrosis patient profile and assuming a 2-year
duration of infection at transplant for infected groups.
Solid line: uninfected patients; bold dashed line: B. multi-
vorans; light dashed line: B. gladioli.
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before the realization that several distinct bacterial species
comprise the B. cepacia complex. More recently, two studies
have assessed differences in outcomes relative to these species
among small numbers of Burkholderia-infected transplant
recipients. De Soyza and colleagues (31) described 11 lung
transplant recipients with CF who had preoperative B. cepacia
complex infection. Analysis of stored bacterial isolates available
from nine of these patients indicated that four who died within
36 days of transplantation were infected with B. cenocepacia. In
contrast, the remaining five patients, three of whom were
infected with B. multivorans and two of whom were infected
with B. vietnamiensis, were alive at the time of the report,
2.5 months to approximately 5 years after transplantation. Aris
and colleagues (32) similarly described 21 lung transplant
recipients who were infected preoperatively with B. cepacia
complex; isolates from 20 patients were available for analysis.
Five of 12 patients infected with B. cenocepacia versus none of
8 patients infected with other species (mostly B. multivorans)
died within 5 months of transplantation (median time to death
of 2.3 mo). Observations such as these, although limited by
small numbers of patients, have led some centers to revise their
transplantation eligibility criteria to exclude B. cenocepacia–
infected patients while offering transplantation to patients
infected with other Burkholderia species.
In the study presented here, we used multivariate Cox
survival models to assess HRs of Burkholderia infection among
several hundred patients with CF who were either wait-listed
for lung transplantation or were lung transplant recipients. This
cohort of 1,554 patients, which includes 171 Burkholderia-
infected lung transplant wait-listed patients, 88 Burkholderia-
infected lung transplant recipients, and 1,295 uninfected control
patients, provides the largest dataset yet analyzed to assess the
relative risks of Burkholderia infection among transplant recip-
ients. Because statistical power is a pervasive concern in studies
of diseases affecting small patient populations, we included
control cases in a 5:1 ratio. Control patients were selected to
address calendar time biases; these were matched on calendar
year of listing in the wait-list analyses, and year of transplant for
the post-transplant analyses. The inclusion of this large set of
control patients supplemented the power of our analysis to the
extent possible.
We used genotypic analyses to confirm the presence of
Burkholderia in each of the infected patients. These assays
have proven superior to the routine phenotypic analyses used
by most clinical microbiology laboratories, which frequently
misidentify Burkholderia and, in general, are not capable of
differentiating species within the B. cepacia complex (33).
Confirmatory genotypic analysis of Burkholderia isolates from
all infected patients allowed us to avoid the potential confound-
ing due to species misidentification that may occur in retro-
spective studies.
We found no significant differences in survival based on
Burkholderia infection status among persons wait-listed for lung
transplantation. A possible explanation for this is that lung
disease among patients entering the waiting list has already
progressed to a degree that masks significant differences in
TABLE 4. HAZARD RATIO, 1- AND 5-YEAR POST-TRANSPLANT SURVIVAL RATES* BY INFECTION
STATUS ADJUSTED FOR TABLE 3 RISK FACTORS (n 5 528)
HR 1-Year Survival, % 5-Year Survival, %
Species/Strain n (%) (95% CI) P† (95% CI) (95% CI)
Uninfected, reference group 440 (83) 1 (NA) NA 80.3 (76.6–84.3) 53.4 (47.7–59.8)
B. cenocepacia‡ 31 (6) 1.73 (0.73–4.11) 0.21 59.6 (40.3–88.1) 47.4 (27.6–81.2)
B. cenocepacia PHDC 8 (1) 1.26 (0.33–4.84) 0.74 56.4 (28.7–100.0) 56.4 (28.7–100.0)
B. cenocepacia Midwest 9 (2) 0.86 (0.24–3.10) 0.82 80.0 (58.1–100.0) 59.6 (33.7–100.0)
B. cenocepacia Otherx 14 (3) 2.52 (1.04–6.12) 0.04 49.6 (27.7–88.9) 32.5 (13.2–80.2)
B. multivorans 32 (6) 0.66 (0.27–1.56) 0.34 88.6 (78.2–100.0) 65.6 (46.0–93.4)
Other Bcck 11 (2) 1.39 (0.53–3.64) 0.50 66.6 (44.7–99.2) 47.2 (25.2–88.3)
B. gladioli 14 (3) 2.23 (1.05–4.74) 0.04 68.6 (48.0–98.1) 0.0 (NA)
For definition of abbreviations, see Table 2.
* Survival rates reported for average covariate profile as follows: age (yr) 5 28.69; probability of being classified as functional
status 1 or 2 5 92%; serum creatinine (mg/dl) 5 0.79; probability of being on a ventilator 5 4%; time infected (yr) 5 2.0.
† P value comparing hazards between infected and uninfected (reference) group.
‡ Results for 31 B. cenocepacia–infected patients produced through a separate parameterization of the model.
x ‘‘B. cenocepacia Other’’ includes all B. cenocepacia strains that are not strain PHDC or Midwest clone.
k ‘‘Other Bcc’’ includes all B. cepacia complex species other than B. cenocepacia and B. multivorans.
TABLE 3. TRANSPLANT RECIPIENT DEMOGRAPHIC MEANS OR PROPORTIONS BY INFECTION STATUS






Other* B. multivorans Other Bcc† B. gladioli
Variable (n 5 440) (n 5 31) (n 5 8) (n 5 9) (n 5 14) (n 5 32) (n 5 11) (n 5 14)
Age, yr 28.7 29.1 31.6 26.0 29.7 27.1 29.4 31.6
Years infected before transplant NA 8.0 10.0 (Ref.) 8.1 6.8‡ 5.4‡ 4.4‡ 2.7‡
NYHA functionalStatus, %
1 or 2 92.0 93.6 75.0 100.0 100.0 90.6 72.7 92.9
3 3.4 6.5 25.0x 0.0 0.0 9.4 27.3x 7.1
On ventilator, % 4.6 3.2 0.0 0.0 7.1 3.1 9.1 0.0
Creatinine, mg/dl 0.8 1.0 0.8 0.8 1.2 0.8 1.3 0.9
Definition of abbreviations: NYHA 5 New York Heart Association; Ref. 5 reference.
* ‘‘B. cenocepacia Other’’ includes all B. cenocepacia strains that are not strain PHDC or Midwest clone.
† ‘‘Other Bcc’’ includes all B. cepacia complex species other than B. cenocepacia and B. multivorans.
‡ Statistically significant difference from B. cenocepacia PHDC patients at P , 0.05.
x Statistically significant difference from uninfected patients at P , 0.05.
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disease progression that may have been apparent earlier. It is
also possible that we had insufficient power to detect real
differences in these small subsets of patients. We also examined
the potential of bias in this analysis due to dependent censoring
for transplants occurring after implementation of the lung
allocation scoring system in May 2005. Of the 1,026 patients
in the wait-listed cohort, only 65 (6%) received lung trans-
plantation after that time; the majority of these patients (57 of
65) were not Burkholderia infected. Our estimates of 1- and
5-year adjusted survival for uninfected wait-listed patients are
very close to those reported in the pre-lung allocation score
OPTN 2005 annual report for patients with CF, where 1-year
adjusted survival was 84% (SE, 3%) and 5-year adjusted survival
was 48% (SE, 3%) (http://www.ustransplant.org/annual_reports/
archives/2005/1211a_rec-dgn_lu.htm). This suggests minimal
impact of competing risks from lung allocation score imple-
mentation on our wait-list survival analysis.
In contrast, we found that post-transplant mortality does
indeed vary with Burkholderia species. Interestingly, in our
analysis, patients infected with B. cenocepacia, in general, did
not have a significantly increased risk of mortality. However,
when this group was further subdivided into patients infected
with either one of the two so-called epidemic strains common in
the United States (strain PHDC and the Midwest clone) or
nonepidemic strains, only the latter group had significantly
increased risk compared with uninfected control subjects. The
reasons for this rather unexpected result are not readily
apparent and this finding must be interpreted with caution.
First, more stringent patient selection for transplantation for
individuals infected with B. cenocepacia could be playing a role.
Although post-transplant risk factors between patients infected
with these two epidemic B. cenocepacia strains and uninfected
control subjects were very similar (Table 3), differential selec-
tion for transplantation not measured by these factors could be
at work. Second, the definition and distinguishing microbiologic
features of ‘‘epidemic strains’’ are not entirely clear. Strain
PHDC and the Midwest clone each have been previously
described as infecting numerous patients with CF in the mid-
Atlantic and Midwestern regions, respectively, of the United
States (34, 35). Although this epidemiology suggests an en-
hanced capacity for interpatient transmission and/or human
infection, the microbiologic determinants of these phenotypes
are unknown. It could be argued that all Burkholderia strains
may be transmissible (or epidemic) given suitable conditions
(24). Furthermore, although this epidemiology might imply that
epidemic strains are more virulent in CF (compared with
nonepidemic strains), the relative virulence of Burkholderia
strains is difficult to assess in the absence of adequate models
of human infection or clearly defined virulence determinants.
B. cenocepacia strain ET12, which is common among patients
Figure 3. Projected benefit (days gained) during the first year (A) and
during the first 5 years (B) after transplantation for 1,026 Burkholderia-
infected or uninfected transplant wait-listed patients with cystic fibrosis.
Benefit was calculated using current lung allocation score factors and
Burkholderia infection status as described in the text. The horizontal lines
in each box are the median adjusted benefit for the group; the boxes
indicate benefit for the middle 50% of the group, and the whiskers
indicate benefit for 70% of the group. Other Bcc 5 B. cepacia complex
species other than B. cenocepacia and B. multivorans.
Figure 4. Lung allocation scores (LAS) for 1,026 Burkholderia-infected
or uninfected transplant wait-listed patients with cystic fibrosis. Scores
were calculated using current LAS factors, infection status, and patients’
corresponding 1-year transplant benefit and urgency as estimated from
Cox multivariate models applied to our data. The horizontal lines
indicate the median adjusted LAS for the group; the boxes contain
the middle 50% of LAS for the group, and the whiskers cover 70% of
the lung allocation scores for the group. Other Bcc 5 B. cepacia
complex species other than B. cenocepacia and B. multivorans.
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with CF in eastern Canada and the United Kingdom, has been
associated with high rates of mortality in several studies in-
volving small numbers of patients with and without lung trans-
plantation (31, 36, 37). Thus, our findings in lung transplant
recipients should not be taken to imply that all epidemic strains
are less virulent than nonepidemic strains in CF. Indeed, as with
strain ET12, the converse may be true. It is interesting to note
that strain PHDC and the Midwest clone reside in B. cenoce-
pacia recA subgroup B, whereas strain ET12 is a member of
recA subgroup A. Clearly, potential differences in virulence and
associated clinical outcomes between distinct B. cenocepacia
strains require further study. This can only be accomplished by
analyzing outcomes among larger cohorts of B. cenocepacia–
infected patients whose isolates have been genotyped to ascer-
tain strain type.
Our analysis indicates that persons infected with B. gladioli
also have a significantly increased risk of mortality after trans-
plantation. This species, although not a member of the B.
cepacia complex, accounts for a significant proportion of
Burkholderia infection in CF. Data from the BcRLR indicate
that, during the last 4 years, B. gladioli accounted for approx-
imately 15 to 20% of new Burkholderia infections among
patients with CF in the United States (unpublished data). The
role that B. gladioli plays in contributing to pulmonary disease
in infected patients with CF, in general, is unknown, and only
a handful of case reports describe outcomes among infected
lung transplant recipients. One describes a patient who de-
veloped postoperative pulmonary, pleural space and chest wall
infection with B. gladioli and died 6 months after transplanta-
tion (38). Another describes a patient with preoperative re-
current subcutaneous abscesses with B. gladioli who did not
survive transplantation (39), whereas two other patients are
reported to have survived despite developing postoperative
wound infections (11). More recently, Kennedy and colleagues
(40) described three patients with CF with chronic B. gladioli
infection who also survived lung transplantation, although two
developed post-transplant infection, one with a mediastinal
abscess that required surgical debridement.
An important finding in our analyses is the lack of increased
post-transplant mortality among patients with CF infected with
B. multivorans. This species accounts for an increasing pro-
portion of Burkholderia infection in CF in the United States and
elsewhere (23, 41); indeed, the incidence of B. multivorans
infection in CF in the United States is now approximately twice
that of B. cenocepacia (unpublished data). Previous studies have
suggested that, among non–transplant recipients, outcomes
associated with B. multivorans infection are comparable to
those observed with Pseudomonas aeruginosa infection (36).
Our finding that patients infected with B. multivorans had post-
transplant outcomes similar to uninfected patients when ad-
justed for other risk factors suggests that infection with this
species should not be considered a contraindication to lung
transplantation. It should be noted, however, that poor out-
comes with B. multivorans infection have been reported,
suggesting that, as in the case of B. cenocepacia, significant
strain-to-strain variation in virulence is possible (42, 43).
We used the models estimating wait-listed candidate and
transplant recipient survival to calculate the projected benefit of
transplantation, assuming transplantation at the time of initial
wait-listing, for each of the 1,026 wait-listed candidates. We
found that approximately one-quarter of candidates were pro-
jected to have a benefit in the first year after transplantation.
However, it is important to note that during the 10-year period
included in our study, the majority of patients with CF were
placed on the wait list relatively early with the expectation that
an organ would not be offered, on average, for 2 years there-
after. Consequently, the projected 1-year benefit tends to be low
(negative values) because at the time of listing these patients
were not yet truly in need of transplantation. The projected 5-
year benefit better reflects what would be expected based on the
covariates known at the time of wait listing. By 5 years after
transplantation, more than half of these patients were projected
to have had a benefit.
We also calculated a modified lung allocation score for each
wait-listed candidate that includes Burkholderia infection status
parameter estimates in the assessment of transplant urgency
and benefit. We found that lung allocation scores of B. multi-
vorans–infected candidates were comparable to those of un-
infected candidates, whereas those of B. gladioli–infected and
some B. cenocepacia–infected candidates (those infected with
nonepidemic strains) were lower. Indeed, many of these latter
scores were below 30, which would place these candidates near
the bottom 5% of the waiting list for lung allocation.
These findings suggest that consideration should be given to
including Burkholderia infection status (i.e., species and possi-
bly strain type) in the lung allocation scoring system. Although
the identification of a species or strain with greater post-trans-
plant risk would reduce the predicted post-transplant benefit of
some patients, the inclusion of infection status could provide
other Burkholderia-infected patients who currently are ex-
cluded from transplant eligibility (i.e., those infected with
species not associated with increased risk) with the opportunity
to receive a transplant. As with other modifications to the lung
allocation scoring system, periodic reevaluation would be
needed to identify changes to the lung allocation algorithm
and the effects of these changes on waiting list and post-
transplant survival. If a less selective population of Burkholde-
ria-infected patients is transplanted than that included in our
cohort, updated analyses will be needed to determine any
changes in mortality that may ensue.
In summary, we have analyzed the most complete microbi-
ologic and outcomes data available to assess lung transplanta-
tion urgency and benefit among a large cohort of Burkholderia-
infected patients with CF. We found that patients infected with
some, but not all, strains of B. cenocepacia are at increased risk
of poor post-transplant outcome. This suggests that important
differences in virulence may exist between strains within this
species. Interestingly, we found that patients infected with B.
gladioli also have a significantly increased risk of post-transplant
mortality. Perhaps most importantly, we show that patients
infected with B. multivorans, which accounts for an increasing
proportion of Burkholderia infection in CF, have no increased
risk when compared with uninfected control subjects, suggesting
that they should not be excluded from lung transplantation
eligibility. Of course, differences in individual host response to
infection almost certainly play an important role in outcomes.
Additional study is needed to better define potential interstrain
differences in outcomes and to identify the bacterial and host
factors involved. It is also important to note that our findings,
which are based on an analysis of a biased patient population
(i.e., lung transplant candidates and recipients), may not extend
to clinical outcomes among Burkholderia-infected patients with
CF as a whole. Additional study is needed to better ascertain the
relative risks of infection with different Burkholderia species
within this larger patient population. Nevertheless, our findings
indicate that Burkholderia infection, in general, should not be
considered an absolute contraindication to lung transplantation
for persons with CF. Inclusion of Burkholderia infection status in
calculating lung allocation scores is warranted.
Conflict of Interest Statement: None of the authors has a financial relationship
with a commercial entity that has an interest in the subject of this manuscript.
370 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 178 2008
Acknowledgment: The authors thank Miles Finley for his thoughtful manuscript
review. The authors are indebted to the patients with CF, their families, and the
CF care centers participating in the CFF Patient Registry, without whose
commitment to CF research this work would not have been possible.
References
1. Annual report of the US Organ Procurement and Transplantation
Network and the Scientific Registry of Transplant Recipients: trans-
plant data 1996–2005. Rockville, MD: Health Resources and Services
Administration, Healthcare Systems Bureau, Division of Transplan-
tation; 2006.
2. Hosenpud JD, Bennett LE, Keck BM, Edwards EB, Novick RJ. Effect
of diagnosis on survival benefit of lung transplantation for end-stage
lung disease. Lancet 1998;351:24–27.
3. Aurora P, Whitehead B, Wade A, Bowyer J, Whitmore P, Rees PG,
Tsang VT, Elliott MJ, de Leval M. Lung transplantation and life
extension in children with cystic fibrosis. Lancet 1999;354:1591–1593.
4. Liou TG, Adler FR, Huang D. Use of lung transplantation survival
models to refine patient selection in cystic fibrosis. Am J Respir Crit
Care Med 2005;171:1053–1059.
5. Liou TG, Adler FR, Cahill BC, FitzSimmons SC, Huang D, Hibbs JR,
Marshall BC. Survival effect of lung transplantation among patients
with cystic fibrosis. JAMA 2001;286:2683–2689.
6. Liou TG, Adler FR, Cox DR, Cahill BC. Lung transplantation and survival
in children with cystic fibrosis. N Engl J Med 2007;357:2143–2152.
7. Egan TM, Murray S, Bustami RT, Shearon TH, McCullough KP,
Edwards LB, Coke MA, Garrity ER, Sweet SC, Heiney DA, et al.
Development of the new lung allocation system in the United States.
Am J Transplant 2006;6:1212–1227.
8. Organ Procurement and Transplantation Network; United Network for
Organ Sharing. Executive summary of the minutes OPTN/UNOS
Board of Directors meeting. St. Louis, MO: Organ Procurement and
Transplantation Network, United Network for Organ Sharing; 2007.
9. Moore J, Murray S, Merion RM, Sweet SC, Sheraton TH. Addition of
PaCO2 as an allocation factor in lung transplantation. Am J Trans-
plant 2007;7:244.
10. Griffith BP, Hardesty RL, Armitage JM, Hattler BG, Pharn SM, Keenan
RJ, Paradis I. A decade of lung transplantation. Ann Surg 1993;218:
310–320.
11. Kanj SS, Tapson V, Davis RD, Madden J, Browning I. Infections in
patients with cystic fibrosis following lung transplantation. Chest 1997;
112:924–930.
12. Kurland G, Orenstein DM. Complications of pediatric lung and heart-
lung transplantation. Curr Opin Pediatr 1994;6:262–271.
13. Massard G, Shennib H, Metras D, Camboulives J, Viard L, Mulder DS,
Tchervenkov CI, Morin JF, Giudicelli R, Noirclerc M. Double-lung
transplantation in mechanically ventilated patients with cystic fibrosis.
Ann Thorac Surg 1993;55:1087–1091.
14. Aris RM, Gilligan PH, Neuringer IP, Gott KK, Rea J, Yankaskas JR.
The effects of panresistant bacteria in cystic fibrosis patients on lung
transplant outcome. Am J Respir Crit Care Med 1997;155:1699–1704.
15. Balfour-Lynn IM, Ryley HC, Whitehead BF. Subdural empyema due to
Burkholderia cepacia: an unusual complication after lung transplan-
tation for cystic fibrosis. J R Soc Med 1997;90:59–64.
16. Chaparro C, Chamberlain D, Maurer J, Winton T, Dehoyos A, Kesten S.
Bronchiolitis obliterans organizing pneumonia (BOOP) in lung trans-
plant recipients. Chest 1996;110:1150–1154.
17. Chaparro C, Maurer J, Gutierrez C, Krajden M, Chan C, Winton T,
Keshavjee S, Scavuzzo M, Tullis E, Hutcheon M, et al. Infection with
Burkholderia cepacia in cystic fibrosis. Am J Respir Crit Care Med
2001;163:43–48.
18. Noyes BE, Michaels MG, Kurland G, Armitage JM, Orenstein DM.
Pseudomonas cepacia empyema necessitatis after lung transplantation
in two patients with cystic fibrosis. Chest 1994;105:1888–1891.
19. Snell GI, de Hoyos A, Krajden M, Winton T, Maurer JR. Pseudomonas
cepacia in lung transplant recipients with cystic fibrosis. Chest 1993;
103:466–471.
20. Egan JJ, McNeil K, Bookless B, Gould K, Corris P, Higenbottam T, Webb
AK, Woodcock AA. Post-transplantation survival of cystic fibrosis
patients infected with Pseudomonas cepacia. Lancet 1994;344:552–553.
21. LiPuma JJ. Burkholderia cepacia complex: a contraindication to lung
transplantation in cystic fibrosis? Transpl Infect Dis 2001;3:149–160.
22. Webb AK, Egan J. Should patients with cystic fibrosis infected with
Burkholderia cepacia undergo lung transplantation? Thorax 1997;52:
671–673.
23. Reik R, Spilker T, LiPuma JJ. Distribution of Burkholderia cepacia
complex species among isolates recovered from persons with or
without cystic fibrosis. J Clin Microbiol 2005;43:2926–2928.
24. LiPuma JJ. Update on the Burkholderia cepacia complex. Curr Opin
Pulm Med 2005;11:528–533.
25. LiPuma JJ, Dulaney BJ, McMenamin JD, Whitby PW, Stull TL,
Coenye T, Vandamme P. Development of rRNA-based PCR assays
for identification of Burkholderia cepacia complex isolates recov-
ered from cystic fibrosis patients. J Clin Microbiol 1999;37:3167–
3170.
26. Mahenthiralingam E, Bischof J, Byrne SK, Radomski C, Davies JE,
Av-Gay Y, Vandamme P. DNA-based diagnostic approaches for
identification of Burkholderia cepacia complex, Burkholderia vietna-
miensis, Burkholderia multivorans, Burkholderia stabilis, and Bur-
kholderia cepacia genomovars I and III. J Clin Microbiol 2000;38:
3165–3173.
27. Coenye T, Spilker T, Martin A, LiPuma JJ. Comparative assessment of
genotyping methods for epidemiologic study of Burkholderia cepacia
genomovar III. J Clin Microbiol 2002;40:3300–3307.
28. Cox DR. Regression models and life tables. J Roy Stat Soc[Ser A] 1972;
34:187–220.
29. Doershuk CF, Stern RC. Timing of referral for lung transplantation for
cystic fibrosis: Overemphasis on FEV1 may adversely affect overall
survival. Chest 1999;115:782–787.
30. Mariencheck WI Jr, Palmer SM, Tapson VF, Davis RD, Durham NC.
Survival following lung transplantation of cystic fibrosis patients
colonized with Burkholderia cepacia [abstract]. Am J Respir Crit
Care Med 2000;161:A720.
31. De Soyza A, McDowell A, Archer L, Dark JH, Elborn SJ, Mahenthir-
alingam E, Gould K, Corris PA. Burkholderia cepacia complex
genomovars and pulmonary transplantation outcomes in patients
with cystic fibrosis. Lancet 2001;358:1780–1781.
32. Aris RM, Routh JC, LiPuma JJ, Heath DG, Gilligan PH. Lung trans-
plantation for cystic fibrosis patients with Burkholderia cepacia
complex: survival linked to genomovar type. Am J Respir Crit Care
Med 2001;164:2102–2106.
33. McMenamin JD, Zaccone TM, Coenye T, Vandamme P, LiPuma JJ.
Misidentification of Burkholderia cepacia in US cystic fibrosis treat-
ment centers: an analysis of 1,051 recent sputum isolates. Chest 2000;
117:1661–1665.
34. Chen JS, Witzmann KA, Spilker T, Fink RJ, LiPuma JJ. Endemicity and
inter-city spread of Burkholderia cepacia genomovar III in cystic
fibrosis. J Pediatr 2001;139:643–649.
35. Coenye T, LiPuma JJ. Population structure analysis of Burkholderia
cepacia genomovar III: varying degrees of genetic recombination
characterize major clonal complexes. Microbiology 2002;149:77–
88.
36. Jones AM, Dodd ME, Govan JR, Barcus V, Doherty CJ, Morris J,
Webb AK. Burkholderia cenocepacia and Burkholderia multivorans:
Influence on survival in cystic fibrosis. Thorax 2004;59:948–951.
37. Ledson MJ, Gallagher MJ, Jackson M, Hart CA, Walshaw MJ. Outcome
of Burkholderia cepacia colonisation in an adult cystic fibrosis centre.
Thorax 2002;57:142–145.
38. Khan SU, Gordon SM, Stillwell PC, Kirby TJ, Arroliga AC. Empyema
and bloodstream infection caused by Burkholderia gladioli in a patient
with cystic fibrosis after lung transplantation. Pediatr Infect Dis J
1996;15:637–639.
39. Jones AM, Stanbridge TN, Isalska BJ, Dodd ME, Webb AK. Burkhol-
deria gladioli: recurrent abscesses in a patient with cystic fibrosis.
J Infect 2001;42:69–71.
40. Kennedy MP, Coakley RD, Donaldson SH, Aris RM, Hohneker K,
Wedd JP, Knowles MR, Gilligan PH, Yankaskas JR. Burkholderia
gladioli: five year experience in a cystic fibrosis and lung trans-
plantation center. J Cyst Fibros 2007;6:267–273.
41. Govan JR, Brown AR, Jones AM. Evolving epidemiology of Pseudo-
monas aeruginosa and the Burkholderia cepacia complex in cystic
fibrosis lung infection. Future Microbiol 2007;2:153–164.
42. Segonds C, Heulin T, Marty N, Chabanon G. Differentiation of
Burkholderia species by PCR-restriction fragment length polymor-
phism analysis of the 16S rRNA gene and application to cystic fibrosis
isolates. J Clin Microbiol 1999;37:2201–2208.
43. Whiteford ML, Wilkinson JD, McColl JH, Conlon FM, Michie JR,
Evans TJ, Paton JY. Outcome of Burkholderia (Pseudomonas)
cepacia colonization in children with cystic fibrosis following a hospital
outbreak. Thorax 1995;50:1194–1198.
Murray, Charbeneau, Marshall, et al.: Burkholderia and CF Lung Transplantation 371
